Tilray (NASDAQ:TLRY) Issues Earnings Results, Misses Expectations By $0.02 EPS

Tilray (NASDAQ:TLRY) announced its quarterly earnings results on Monday. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02), Briefing.com reports. Tilray had a negative return on equity of 2.65% and a negative net margin of 30.26%. The business had revenue of $229.90 million during the quarter, compared to analysts’ expectations of $226.20 million. During the same period in the previous year, the business earned ($0.15) EPS. The business’s revenue was up 24.8% compared to the same quarter last year.

Tilray Stock Performance

Shares of TLRY stock opened at $2.01 on Wednesday. Tilray has a 12 month low of $1.60 and a 12 month high of $3.40. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.18 and a current ratio of 1.92. The company’s fifty day moving average price is $1.78 and its 200-day moving average price is $1.89.

Wall Street Analyst Weigh In

A number of brokerages recently commented on TLRY. Canaccord Genuity Group dropped their price target on Tilray from $4.25 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, April 10th. CIBC decreased their price objective on Tilray from $2.25 to $2.00 and set a “neutral” rating for the company in a report on Wednesday, April 10th. Finally, Alliance Global Partners boosted their target price on shares of Tilray from $2.25 to $2.75 and gave the company a “neutral” rating in a report on Friday, April 5th.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.